EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

DNA methylation profiling predicts postsurgical regrowth in SF1-lineage nonfunctioning pituitary neuroendocrine tumors

Morten Winkler Møller iD, Grayson A Herrgott, Marianne Skovsager Andersen iD, Bo Halle, Christian Bonde Pedersen, Henning Bünsow Boldt, Jeanette K Petersen, Christopher Powell, Ana Valeria Castro, Frantz Rom Poulsen

Neuro-Oncology · 2026

DOI: 10.1093/neuonc/noaf269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2026. Verfasst von Morten Winkler Møller und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Odense University Hospital (M.W.M., B.H., C.B.P., F.R.P.). Hauptthemen laut MEDLINE: DNA Methylation, Pituitary Neoplasms, Neuroendocrine Tumors, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Foundation, Brødrene Hartmanns Fond, Tornøes og Høyrups Fond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Nonfunctioning pituitary neuroendocrine tumors (NFPitNETs) account for ∼30-35% of PitNETs; ∼75% arise from the SF1 lineage. Recurrence remains common despite resection (∼30% in 10 years), and routine histopathology/IHC has limited value in predicting recurrence risk. This study evaluated whether DNA methylation profiling improves recurrence risk stratification. Materials and Methods Genome-wide tissue methylation (Illumina EPIC v1, 850K) was analyzed in 117 retrospective NFPitNETs with clinical and imaging follow-up. Unsupervised consensus clustering defined methylation-based subgroups, followed by supervised differential methylation analysis to identify cluster-specific differentially methylated probes (DMPs). A classifier was trained using these signatures, with predicted subgroup memberships correlated with regrowth and progression-free survival (PFS). To ensure reliable estimations, longitudinal mixed-effects models were restricted to the interval of model stability (∼9 years), reflecting cohort follow-up. External validation was performed in 3 independent cohorts.

Results

Five clusters (k1-k5) emerged: 4 SF1-positive-predominant (k1, k2, k3, and k5) and 1 TPIT/PIT1-enriched NFPitNETs (k4). Among the 562 DMPs, many mapped to genes regulating cell-cycle and immune pathways. Compared with k1-k2, k3, k4, and k5 possessed significantly higher recurrence risk. Within SF1-lineage tumors, k3 exhibited postoperative tumor-volume expansion beginning at ∼6 years. The methylation-based classifier achieved ∼97% accuracy in assigning clusters and maintained prognostic separation across independent cohorts.

Conclusions

DNA methylation profiling identifies biologically and clinically distinct NFPitNET subgroups, particularly within the SF1 lineage, and may enhance prediction of recurrence risk. Prospective validation and demonstration of clinical utility are warranted to support integration into precision management workflows.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA MethylationPituitary NeoplasmsNeuroendocrine TumorsNeoplasm Recurrence, LocalBiomarkers, TumorHumansMaleFemaleMiddle AgedRetrospective StudiesPrognosisAdultFollow-Up StudiesAgedSurvival Rate

Stichwörter der Autor:innen

DNA methylationSF1machine learningnonfunctioning ­PitNETsregrowth

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Neurosurgery, Odense University Hospital (M.W.M., B.H., C.B.P., F.R.P.).
  • Department of Clinical Research and BRIDGE (Brain Research-Inter Disciplinary Guided Excellence), University of Southern Denmark (M.W.M., B.H., C.B.P., H.B.B., J.K.P., F.R.P.).
  • Hermelin Brain Tumor Center, Omics Laboratory, Department of Neurosurgery, Henry Ford Health (G.A.H., C.P., A.V.C.).
  • Department of Endocrinology, Odense University Hospital (M.S.A.).
  • Department of Pathology, Odense University Hospital (H.B.B., J.K.P.).
  • College of Human Medicine, Department of Physiology, Michigan State University (A.V.C.).

ORCID-Profile: Morten Winkler Møller, Marianne Skovsager Andersen

Förderung

  • Novo Nordisk Foundation
  • Brødrene Hartmanns Fond
  • Tornøes og Høyrups Fond
  • Beckett-Fonden, Aase og Ejnar Danielsens Fond
  • Odense University Hospital

Zitieren

APA

Møller, M. W., Herrgott, G. A., Andersen, M. S., Halle, B., Pedersen, C. B., Boldt, H. B., Petersen, J. K., Powell, C., Castro, A. V., & Poulsen, F. R. (2026). DNA methylation profiling predicts postsurgical regrowth in SF1-lineage nonfunctioning pituitary neuroendocrine tumors. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf269

Vancouver

Møller MW, Herrgott GA, Andersen MS, Halle B, Pedersen CB, Boldt HB, et al. DNA methylation profiling predicts postsurgical regrowth in SF1-lineage nonfunctioning pituitary neuroendocrine tumors. Neuro-Oncology. 2026. doi:10.1093/neuonc/noaf269

BibTeX
@article{Mller2026,
  author = {Møller, Morten Winkler and Herrgott, Grayson A and Andersen, Marianne Skovsager and Halle, Bo and Pedersen, Christian Bonde and Boldt, Henning Bünsow and Petersen, Jeanette K and Powell, Christopher and Castro, Ana Valeria and Poulsen, Frantz Rom},
  title = {DNA methylation profiling predicts postsurgical regrowth in SF1-lineage nonfunctioning pituitary neuroendocrine tumors},
  journal = {Neuro-Oncology},
  year = {2026},
  doi = {10.1093/neuonc/noaf269}
}
Kostenlos starten →